ISG15, G1P2, IFI15, UCRP, ISG15 Ubiquitin-like modifier.
Greater than 98.0% as determined by SDS-PAGE.
ISG15, G1P2, IFI15, UCRP, ISG15 Ubiquitin-like modifier.
ISG15 consists of two tandem ubiquitin-like domains that share a similar three-dimensional structure with ubiquitin and other ubiquitin-like modifiers such as NEDD8 and SUMO1 . This structural similarity allows ISG15 to be covalently attached to target proteins in a process known as ISGylation . ISGylation is a post-translational modification that can alter the function, localization, and stability of target proteins, thereby modulating various cellular processes.
The expression of ISG15 is strongly induced by type I interferons (IFNs) as a primary response to viral infections and other cellular stress stimuli . It is also upregulated by bacterial infections through the Janus kinase/signal transducer and activator of transcription (Jak/STAT) signaling pathway . ISG15 is secreted from monocytes and lymphocytes and functions both intracellularly and extracellularly .
ISG15 has several important biological roles:
Recombinant human ISG15 is produced using Escherichia coli (E. coli) expression systems . The recombinant protein is typically purified and characterized to ensure high purity and activity. It is used in various research applications, including studies on ISGylation, antiviral responses, and immune regulation.
Recombinant ISG15 is available in different formulations, including carrier-free versions that do not contain bovine serum albumin (BSA), which can interfere with certain applications . The protein is usually supplied as a lyophilized powder or in solution and requires careful handling to maintain its stability and activity .
Recombinant ISG15 is widely used in research to: